AusperBio Secures $63 Million to Propel Hepatitis B Therapies
AusperBio Secures $63 Million to Accelerate Hepatitis B Therapies
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively known as AusperBio) have announced the successful closing of their Series B2 financing round, raising an impressive $63 million. This funding signifies a strong vote of confidence from existing investors, reflecting their belief in AusperBio's innovative approach to treating chronic hepatitis B (CHB).
Investors Show Confidence in AusperBio’s Vision
The financing round was co-led by prominent organizations including Qiming Venture Partners, alongside other strategic investors such as HanKang Capital and CDH Investments. This collaboration underscores the strong interest in AusperBio's goal to develop targeted oligonucleotide therapies aimed at achieving a functional cure for CHB.
Purpose of the Financing
With the proceeds from this financing, AusperBio is set to advance its clinical development of AHB-137, the company's lead product candidate. This includes the ongoing pivotal trial and several Phase II combination studies. Additionally, the funding will facilitate the global expansion of these clinical developments, as well as the advancement of the proprietary Med-Oligo™ ASO platform, which is essential for their pipeline's growth and upcoming manufacturing partnerships.
Insights from the Leadership Team
Dr. Guofeng Cheng, the co-founder and CEO of AusperBio, expressed gratitude for the support from their investors and emphasized how this financial backing is crucial in pushing their clinical programs forward. He stated that this funding positions the company to speed up the development of AHB-137 and expand its global clinical initiatives.
Setting New Standards for Chronic Hepatitis B Treatment
Dr. Chris Yang, the co-founder and Chief Scientific Officer of AusperBio, shared insights about AHB-137, noting it as the first candidate from their Med-Oligo™ platform to reach the pivotal development phase. The encouraging data gathered so far demonstrates its potential as a mainstay therapy for CHB. He also mentioned that the financing would help advance the next generation combination therapy for this challenging condition.
Driving Forward with Advanced Solutions
AusperBio is recognized for pioneering a fresh approach to addressing chronic hepatitis B, which poses a significant public health concern worldwide. William Hu, Managing Partner of Qiming Venture Partners, stated his confidence in the AusperBio team and the transformative therapies they are developing for patients globally.
About AHB-137
AHB-137 is a novel unconjugated antisense oligonucleotide (ASO) that is being developed with AusperBio's Med-Oligo™ technology. This investigational medicine aims to provide a functional cure for chronic hepatitis B with encouraging clinical data supported by presentations at significant global conferences. Currently, AHB-137 is progressing through its Phase I and multiple Phase II trials, moving closer to a potential breakthrough in treatment for HBV.
About AusperBio
AusperBio is a biopharmaceutical company dedicated to revolutionizing treatment methodologies through oligonucleotide and targeted delivery technologies. With endeavors both in the USA and China, their mission focuses on overcoming chronic hepatitis B infection. Their Med-Oligo™ ASO platform enhances the current ASO therapeutics significantly by incorporating innovative insights into ASO design, enabling effective treatments for viral infections and other serious medical conditions.
Contact Information
For additional information, please reach out to:
Media Contact
Email: info@ausperbio.com
Investor Relations Contact:
Tel: 650-888-1756 (US)
Email: investor@ausperbio.com
Frequently Asked Questions
What is the primary focus of AusperBio?
AusperBio is focused on developing targeted therapies to achieve a functional cure for chronic hepatitis B.
How much funding did AusperBio raise in their latest financing round?
AusperBio raised $63 million in their Series B2 financing round.
What is AHB-137?
AHB-137 is a novel antisense oligonucleotide developed by AusperBio aimed at curing chronic hepatitis B.
Who are some of the investors in AusperBio?
Investors include Qiming Venture Partners, HanKang Capital, and CDH Investments.
What is the Med-Oligo™ ASO platform?
The Med-Oligo™ ASO platform is AusperBio's proprietary technology designed to enhance the effectiveness of oligonucleotide therapies.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.